NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 319 filers reported holding NOVOCURE LTD in Q3 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $91,000 | -19.5% | 1,315 | -3.6% | 0.02% | -10.0% |
| Q1 2022 | $113,000 | +8.7% | 1,364 | -1.1% | 0.02% | +17.6% |
| Q4 2021 | $104,000 | -36.6% | 1,379 | -2.1% | 0.02% | -41.4% |
| Q3 2021 | $164,000 | -47.8% | 1,409 | -0.4% | 0.03% | -49.1% |
| Q2 2021 | $314,000 | +1552.6% | 1,414 | +895.8% | 0.06% | +1325.0% |
| Q1 2021 | $19,000 | -24.0% | 142 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $25,000 | +56.2% | 142 | 0.0% | 0.01% | +20.0% |
| Q3 2020 | $16,000 | +100.0% | 142 | 0.0% | 0.01% | +66.7% |
| Q2 2020 | $8,000 | 0.0% | 142 | +14.5% | 0.00% | -25.0% |
| Q1 2020 | $8,000 | – | 124 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |